Latest Earnings Results: Q2 '26
Estimated EPS
-$0.19
Reported EPS
$0.01
Surprise
+105.32%
Estimated Rev
$111.01M
Reported Rev
$114.44M
Surprise
+3.09%
• Reported GAAP EPS of -$0.60 down -257.89% YoY • Reported revenue of $114.44M up 11.44% YoY
Bullish Takeaway
GeneDx Holdings demonstrated strong growth in test volumes and whole exome and genome sequencing revenues, while securing additional capital through an expanded term loan facility with Blackstone to support operations.
Bearish Takeaway
GeneDx Holdings faces significant financial challenges, including a $31.3 million impairment charge, a net loss of $81.1 million for the six-month period, and an unremediated material weakness in internal controls.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.06 | -- | -- | N/A |
Q2 '26 | -$0.19 | $0.01 | 105.32% | BEAT |
Q1 '26 | -$0.01 | -$0.28 | -1766.67% | MISSED |
Q4 '25 | $0.12 | $0.14 | 16.85% | BEAT |
Q3 '25 | $0.42 | $0.49 | 15.88% | BEAT |